Cargando…

Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration

OBJECTIVES: To evaluate the outcomes of delayed intravitreal injections (IVIs) caused by the outbreak of coronavirus disease 2019 (COVID-19), in patients with neovascular age-related macular degeneration (nAMD). METHODS: nAMD patients with scheduled IVIs between March 1(st) and April 30(th), 2020 we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nassisi, Marco, Pozzo Giuffrida, Francesco, Milella, Paolo, Ganci, Simone, Aretti, Andrea, Mainetti, Claudia, Dell’Arti, Laura, Mapelli, Chiara, Viola, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107548/ https://www.ncbi.nlm.nih.gov/pubmed/37069537 http://dx.doi.org/10.1186/s12886-023-02864-x

Ejemplares similares

Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment
por: Yeter, D.Y., et al.
Publicado: (2021)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2018)

Reasons for Delayed Anti-VEGF Treatment During COVID-19 Lockdown and Clinical Impact in Neovascular Age-Related Macular Degeneration
por: Zarranz-Ventura, Javier, et al.
Publicado: (2023)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou, Stamatina A, et al.
Publicado: (2017)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature
por: Di Nicola, Maura, et al.
Publicado: (2015)

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
por: Yang, Shiqi, et al.
Publicado: (2016)

Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration
por: Strunz, Tobias, et al.
Publicado: (2022)

Choroidal Modifications Preceding the Onset of Macular Neovascularization in Age-Related Macular Degeneration
por: Arrigo, Alessandro, et al.
Publicado: (2021)

Histology of neovascular myopic macular degeneration
por: Jonas, Shefali B., et al.
Publicado: (2021)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration
por: Arai, Yusuke, et al.
Publicado: (2020)

Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy
por: Reiter, Gregor S., et al.
Publicado: (2022)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
por: Han, Fangyuan, et al.
Publicado: (2022)

Melatonin Inhibits VEGF-Induced Endothelial Progenitor Cell Angiogenesis in Neovascular Age-Related Macular Degeneration
por: Lin, Liang-Wei, et al.
Publicado: (2023)

Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration
por: Hirata, Akira, et al.
Publicado: (2017)

Adaptive Optics of Kyrieleis Plaques in Varicella Zoster Virus-Associated Posterior Uveitis: A Multimodal Imaging Analysis
por: Milella, Paolo, et al.
Publicado: (2023)

Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study
por: Bandello, Francesco, et al.
Publicado: (2020)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa, Ana Catarina, et al.
Publicado: (2016)

Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy
por: Prea, Selwyn M., et al.
Publicado: (2015)

Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration
por: Wen, Joanne C., et al.
Publicado: (2017)

Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration
por: Mantel, Irmela, et al.
Publicado: (2019)

Aqueous proteins help predict the response of patients with neovascular age-related macular degeneration to anti-VEGF therapy
por: Cao, Xuan, et al.
Publicado: (2022)

Influence of vitreomacular interface score on treatment outcomes of anti-VEGF therapy for neovascular age-related macular degeneration
por: Miyata, Manabu, et al.
Publicado: (2021)

OCT-Derived Radiomic Features Predict Anti–VEGF Response and Durability in Neovascular Age-Related Macular Degeneration
por: Kar, Sudeshna Sil, et al.
Publicado: (2022)

Suspension of Anti-VEGF Treatment Does Not Affect Expansion of RPE Atrophy in Neovascular Age-Related Macular Degeneration
por: Chujo, Shinichiro, et al.
Publicado: (2023)

Decrease in Anti-VEGF Injections After Post-injection Endophthalmitis in Patients With Neovascular Age-Related Macular Degeneration
por: Binczyk, Natalia M., et al.
Publicado: (2023)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study
por: Corazza, Paolo, et al.
Publicado: (2021)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial
por: Russo, Andrea, et al.
Publicado: (2018)

Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
por: Ricci, Federico, et al.
Publicado: (2020)

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2021)

Peripapillary and macular microvasculature in neovascular age-related macular degeneration in long-term and recently started anti-VEGF therapy versus healthy controls
por: Türksever, Cengiz, et al.
Publicado: (2023)

Fluid dynamics between injections in incomplete anti-VEGF responders within neovascular age-related macular degeneration: a prospective observational study
por: Gigon, Anthony, et al.
Publicado: (2022)

Expanding the clinical spectrum of the mitochondrial mutation A13084T in the ND5 gene
por: Brusa, Roberta, et al.
Publicado: (2020)

Recent advances and future directions for the pharmacogenetic basis of anti-VEGF treatment response in neovascular age-related macular degeneration
por: Riaz, Moeen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rjm6cdg6889jo2chfh2p83bnbu